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Background. The most appropriate therapy for papillary microcarcinoma (PMC) is controversial. Methods. We reviewed the
therapy and outcome of 407 patients with PMC. Results. Three hundred-eighty patients underwent total thyroidectomy, and 349
patients received I-131 therapy. The median followup was 5.3 years. Forty patients developed recurrent disease. On univariate
analysis, development of disease recurrence was correlated with histological tumor size > 0.8cm (P = 0.0104), age < 45 years (P =
0.043), and no I-131 therapy (P < 0.0001). On multivariate analysis, histological tumor size > 0.8cm, positive lymph nodes, and
no I-131 therapy were signiﬁcant. The 5-year RFS for patients treated with I-131 was 95.0% versus 78.6% (P < 0.0001) for patients
not treated with I-131. Patients with lymph node metastasis who did not receive I-131 had a 5-year RFS of 42.9% versus 93.2%
(P < 0.0001) for patients who received I-131.Conclusions. Recommend I-131 remnant ablation for patients with PMC, particularly
patients with lymph node metastasis.
1.Introduction
Papillary thyroid cancer is associated with an excellent
prognosis, with cancer-speciﬁc survival of >90% [1, 2].
Tumor size has been established as prognostic factor [3–
5]. As such, the World Health Organization deﬁned tumors
≤1cm in greatest dimension as a separate entity, papillary
microcarcinoma (PMC) [6]. Given the overall excellent
prognosis of PMC, there is controversy regarding the most
appropriate treatment as one must weigh recurrence risk
versus treatment toxicity. The appropriate extent of surgery
and the utility of I-131 therapy in patients with PMC are
unclear. Treatment recommendations, represented in the lit-
erature, range from observation alone to total thyroidectomy
followed by I-131 therapy [7–10].
The purpose of this study is to identify patient and
tumor prognostic factors for recurrent disease in patients
with PMC, and to examine the impact of I-131 therapy for
patients with PMC.
2.Methods andMaterials
All patients with thyroid cancer who were referred to the
Department of Radiation Oncology at Washington Univer-
sity were entered into a departmental database beginning in
1959. This data set was interrogated to identify patients older
than 18 years with papillary microcarcinoma (≤1.0cm).
Fourhundred-sevenpatientsmeetingtheseinclusioncriteria
were identiﬁed. Medical records were reviewed, and the
following data were reviewed for this group: demographic2 ISRN Endocrinology
information, extent of initial surgery, various histological
parameters, I-131 treatment, and outcome. Lymph node
status was determined from pathology reports and whole-
body I-131 scintigraphy (WBS) results.
The majority of patients underwent total thyroidectomy
(n = 380, 93.4%); 25 patients underwent lobectomy and
2 had surgery of unknown extent. Surgery was followed
by I-131 therapy in 349 patients (85.7%). The reason
for omitting I-131 in the remaining 14.3% of patients is
unknown. No patients underwent >1 I-131 administration
as initial therapy. The median administered activity of I-
131 was 100mCi (range 25–250mCi). Three to 5 days
after treatment, WBS was performed. Followup consisted of
regularly scheduled physical examination, measurement of
serum thyroglobulin (Tg) level (after the mid-1990s), and
diagnostic WBS (performed with 5mCi I-131).
The patient population consisted of 321 woman and 86
men; their median age at diagnosis was 45 years (range
18–80 years). The tumor histology was described as pure
papillaryin317patients,follicularvariantin87patients, and
tall cell variant in 4 patients. The median tumor size was
0.7cm (range 0.1–1.0cm). Additional histological features
are depicted in Table 1. The patients were followed for a
median of 5.3 years (range from 0.2 to 51 years).
Logistic regression analysis was performed to determine
the correlation between various parameters and the devel-
opment of recurrent disease. Multivariate logistic regres-
sion was done using Cox proportional hazards modeling.
Recurrent disease was deﬁned as the development of positive
WBS on clinical report, positive FDG-PET on clinical report,
positive pathology, or a detectable Tg level (>1ng/mL),after
a disease-free interval. The time to recurrence was deﬁned
as diﬀerence between the date of initial surgery and date
of recurrence. Recurrence-free survival was based on the
development of recurrent thyroid cancer. The Kaplan-Meier
method was used to calculate survival rates.
3. Results
Of the 407 total patients, 40 (9.8%) developed recurrent
disease at a median of 4.2 years (0.3–38 years). The location
of ﬁrst recurrence was as follows: 23 patients had disease
recurrence in neck nodes, 10 in the thyroid bed only, 3
in multiple distant sites, 2 in the neck and lung, 1 in the
lung only, and 1 by Tg elevation without a site of disease
identiﬁed on imaging. Salvage therapy consisted of surgery
in 5 patients, I-131 therapy in 17 patients, both surgery and
I-131 therapies in 14 patients, and observation in 4 patients.
Three (0.7%) patients died of thyroid cancer at a median of
38.6 years after diagnosis.
On univariate analysis, the development of disease
recurrence was correlated with histological tumor size >
0.8cm (P = 0.0104), age < 45 years (P = 0.043), and
no I-131 therapy (P<0.0001). We found no correlation
between the development of recurrent disease and gender,
histological subtype, positive lymph nodes on ﬁrst WBS or
pathology, vascular invasion, capsular invasion, soft tissue
invasion, or positive surgical margins. On multivariate
analysis, histological tumor size > 0.8cm, positive lymph
Table 1: Characteristics of patient population (N = 407).
Characteristic N( %)
Age: median (range) 45 years (18–80)
Gender
Male 86 (21.1)
Female 321 (78.9)
Extent of surgery
Lobectomy 27 (6.6)
Total thyroidectomy 380 (93.3)
Multifocal tumor 188 (46.2)
Capsular invasion 126 (31.0)
Vascular invasion 14 (3.4)
Soft tissue invasion 68 (16.7)
Positive surgical margin 73 (17.9)
Positive lymph node 153 (37.6)
Tumor size > 0.8cm 132 (32.4)
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Figure 1
nodes,andnoI-131therapyweresigniﬁcant(Table 2).There
wasnothresholdfortumorsizebelowwhichpatientsdidnot
experience recurrence; patients with recurrent disease had a
median tumor size of 0.95cm (0.1–1.0cm).
The 5-year RFS for patients treated with I-131 was 95.0%
compared to 78.6% for patients not treated with I-131 (P<
0.0001) (Figure 1). I-131 therapy continued to be associated
with improved RFS in the 231 patients with tumors ≤0.8cm;
the 5-year RFS were 96.3% and 92.6%, respectively, (P =
0.004) for such patients treated and not treated with I-131.
Patients with and without lymph node metastasis treated
with I-131 had 5-year RFS of 93.2% and 96.2%, respectively
(P = NS). Patients not treated with I-131 experienced a
signiﬁcantly worse 5-year RFS compared to those treated
with I-131 regardless of lymph node status. Patients without
lymphnodemetastasiswhowerenottreatedwithI-131hada
5-year RFS of 88.0% versus 96.2% (P<0.0001), for patientsISRN Endocrinology 3
Table 2: Logistic regression analysis for correlation of various risk factors with development of recurrent disease.
Characteristic Number with recurrence (%) Univariate
P value
Relative risk
(95% CI)
Multivariate
P value
Age
≥45 years 10/207 (4.8)
<45 years 30/200 (15.0) 0.042 NS
Gender
Male 7/86 (8.1)
Female 33/321 (10.3) 0.248 NS
Multifocal tumor
Yes 20/188 (10.6) 0.462 NS
No 20/219 (9.1)
Capsular invasion
Yes 15/126 (11.9) 0.389 NS
No 25/281 (8.9)
Vascular Invasion
Yes 3/14 (21.4) 0.823 NS
No 37/393 (9.4)
Soft tissue invasion
Yes 8/68 (11.8) 0.937 NS
No 32/339 (9.4)
Positive surgical margin
Yes 8/73 (11.0) 0.654 NS
No 32/334 (9.6)
Positive lymph nodes
Yes 19/153 (12.4) 0.4266 2.3 (1.2–4.6) 0.0150
No 21/252 (8.3)
Tumor size
>0.8cm 25/132 (18.9) 0.0104 2.1 (1.1–4.1) 0.0250
≤0.8cm 15/275 (5.5)
I-131 therapy
No 20/51 (39.2) <0.0001 8.6 (4.4–17.1) <0.0001
Yes 20/349 (5.7)
treated with I-131. Patient with lymph node metastasis who
didnotreceiveI-131hada5-yearRFSof42.9%versus93.2%
(P<0.0001) for patients who received I-131 (Figure 2).
Acute toxicity from I-131 was not recorded. Only one
patient treated with I-131 had developed a chronic toxicity,
lacrimal duct stenosis (0.3%).
4. Discussion
Patients with PMC have very low mortality [3, 11, 12].
However, 4–16% of patients with PMC develop recurrent
disease with many of these patients developing distant
metastasis [3, 8, 11–14]. As such, an appropriate balance
between insuﬃcient treatment, putting patients at risk for
recurrence, and overly aggressive therapy, subjecting patients
to undo toxicity, must be found for patients with PMC.
We were able to identify several treatment- and tumor-
related prognostic factors in our cohort. However, our
population represents patients referred for consideration of
1-131 therapy at a large academic medical center. As a
result, our population may not be representative of the entire
population with PMC but may be a higher-risk population.
However, the RFS and cancer mortality for our patients are
in line with those reported in other studies [3, 8, 11–14].
Further, our series is among the largest studied to date.
Lymph node status and tumor size were the only tumor-
related independent risk factorsfor recurrence in our cohort.
Many authors have advocated the use of tumor size to
dictate treatment decisions Lo rt al. [15], Noguchi et al.
[16], Roti et al. [17], Lin et al. [18]. Although we found
tumor size >0.8cm to be associated with recurrence, we were
unable to identify a size threshold below which there was no
risk of recurrence. Further, the prognostic value of lymph
node status in patient with PMC has been well established
[11, 13, 19], and lymph node status at presentation may
be independent of tumor size in PMC [11, 20, 21]. In
addition, the risk of positive lymph nodes at diagnosis
for PMC has been reported to be 25–43.3% [8, 11–13].4 ISRN Endocrinology
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Therefore, basing treatment decisions solely on tumor size
seems inappropriate.
Agegreaterthan45yearsatdiagnosisisapoorprognostic
factor in papillary thyroid cancer (AJCC staging manual
2009). However, age has not consistently been found to
predictforoutcomeinpatientswithPMC[11,20]suggesting
that other risk factors, such as lymph node status, soft
tissue invasion, and vascular invasion, are more important
predictors of cancer biology than age in patients with small
thyroid tumors [11–14, 20]. In our cohort, we found that
age less than 45 years at diagnosis was a poor prognostic
factor on univariate analysis. However, the younger patients
in our cohort had larger tumors, more frequent lymph node
metastasis, and were less likely to receive I-131 therapy (data
not presented).
Multifocality has been reported in more than 30% of
patients with PMC [3, 7, 11, 20]. Although multifocality
was not predictive of outcome in our cohort, several authors
have identiﬁed multifocal disease as a poor prognostic factor
[11–14, 20]. Given the high rates of multifocality and
the possible association with poor outcome, we advocate
total thyroidectomy for both therapeutic and prognostic
purposes.
Although there is a body of literature that advocates
the use of I-131 therapy for patients with PMC (particu-
larly those patients with poor histological features) (ATA
guidelines) [7, 11, 12, 22, 23], few studies have been
able to demonstrate a clinical beneﬁt of I-131 therapy for
patients with PMC [11]. In our cohort, I-131 treatment
was correlated with improved RFS; patients undergoing
I-131 therapy had a 5-year RFS of 96%. I-131 therapy
also was associated with improved RFS in the subsets of
our patients with tumors ≤0.8cm and in node-negative
patients. In addition to this apparent therapeutic beneﬁt,
remnant ablation with I-131 allows for increased sensitivity
of thyroglobulin measurements for detection of recurrences
(ATA). WBS after I-131 therapy also provides additional
prognostic information by more frequent identiﬁcation of
lymph node and distant metastasis compared with pretreat-
ment diagnostic I-131 scans [24, 25].
Although I-131 therapy is well tolerated, it is not
without toxicity. Patients undergoing I-131 treatment expe-
rience both acute and chronic toxicity. Prior to treatment,
patients are frequently profoundly hypothyroid. However,
the availability of recombinant human thyroid stimulating
hormone allows patients to be treated with I-131 without
hypothyroidism associated with thyroid hormone with-
drawal [26, 27]. After treatment with I-131, patients rarely
experience headache, fatigue, nausea, and vomiting acutely
[28]. More commonly, patients develop acute sialoadenitis
[29]. Typically, acute toxicity resolves rapidly. Patients also
can develop chronic toxicity from I-131, such as xerostomia
and subsequent dental caries [30], lacrimal duct dysfunc-
tion [31], chronic sialoadenitis [32], and rarely second
malignancy [33]. I-131 toxicity is dose dependent; patients
receiving higher activities of I-131 (>150mCi) experience
increased toxicity [34]. However, despite these toxicities, the
long-term quality of life of patients treated for diﬀerentiated
thyroid cancer has been demonstrated to be similar to that of
the normal population [35].
As noted above, 4–16% of patients with PMC develop
recurrent disease [3, 8, 11–14]. Cancer recurrence not only
negatively aﬀects physical health, but also impacts mood,
stress, and overall quality of life [36–38]. Furthermore, fear
of recurrence is associated with poor quality of life for cancer
patients and their families [39, 40]. While not speciﬁcally
studied in thyroid cancer, treatment decisions have been
shown to impact fear of cancer recurrence [39, 41, 42].
Further study is needed to determine if more aggressive
therapy for PMC, such as I-131 treatment, would allow for
improved quality of life by decreasing recurrence or fear of
recurrence.
5. Conclusions
Although patients with PMC have excellent overall survival,
a subset of patients will develop recurrent disease. We were
able to identify clinical characteristics that predicted for
recurrent disease: greater tumor size, positive lymph nodes,
and lack of I-131 therapy. We thus recommend that patients
with PMC, particularly those with involved lymph nodes,
be treated with thyroidectomy followed by thyroid remnant
ablation with I-131.
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